PTN Oct 2024 2.500 call
- PR Newswire
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the initiation of a Phase 2 clinical study of bremelanotide for the treatment of obesity. The clinical study will evaluate the safety and efficacy of bremelanotide, a melanocortin 4 receptor (MC4R) agonist, co-administered with tirzepatide (GLP-1/GIP) in obese patients. The primary endpo
- Zacks
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?
Palatin Technologies (PTN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GuruFocus.com
Palatin Technologies Inc (PTN) (Q3 2024) Earnings Call Transcript Highlights: Navigating ...
Despite a dip in product sales, PTN progresses in clinical developments and maintains a stable financial footing.
